Can Cytokines be used as an Activation Marker in Rheumatoid Arthritis?

Basit Öğe Kaydı
dc.authorid0000-0001-5472-7465en_US
dc.authorid0000-0002-2998-263Xen_US
dc.authorid0000-0002-3060-1507en_US
dc.authorid0000-0002-0774-2766en_US
dc.authorid0000-0002-4936-3705en_US
dc.contributor.authorKaya, Fatih Öner
dc.contributor.authorCeylan, Yeşim
dc.contributor.authorÖngen İpek, Belkız
dc.contributor.authorÖzünal, Zeynep Güneş
dc.contributor.authorSezgin, Gülbüz
dc.contributor.authorNalbant, Selim
dc.date.accessioned2024-07-12T21:03:27Z
dc.date.available2024-07-12T21:03:27Z
dc.date.issued2021en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractAims: The etiopathogenesis of Rheumatoid Arthritis (RA) is not clearly understood. However, the role of the cytokines play an important part in this mechanism. We aimed to bring a new approach to the concept of 'remission' in patients with RA. Background: RA is a chronic, autoimmune, inflammatory disease that involves small joints in the form of symmetrical polyarthritis and progresses with exacerbations and remissions. Pain, swelling, tenderness and morning stiffness are typical of the joints involved. Although it is approached as primary joint disease, a wide variety of extra-articular involvements may also occur. It is an interesting pathophysiological process, the exact cause of which is still unknown, with many environmental, genetic and potentially undiscovered possible factors in a chaotic manner. Objective: In this cross-sectional study, sedimentation rate (ESR), C- Reactive protein (CRP), Tumor necrosis factor (TNF)-?, soluble-TNF-? receptor (TNF-R), Interleukin (IL)-1B and IL-10 were measured in three groups which were healthy volunteers, patients with RA in the active period, and patients with RA in remission. Disease activity score-28 (DAS-28) was calculated in active RA and RA in remission. Methods: This study included 20 healthy volunteers, 20 remission patients with RA and 20 active RA patients. Venous blood samples were collected from patients in both healthy and RA groups. Results: RA group consisted 43 (71.6%) female and 17 (28.4%) male. Control group consisted 11 (55%) female and 9 (45%) male. TNF-R was significantly high only in the active group according to the healthy group (p=0.002). IL-10 was significantly high in active RA, according to RA in remission (p=0.03). DAS-28 was significantly high in active RA, according to RA in remission (p=0.001). In the active RA group, ESR and TNF-R had a positive correlation (r:0.442; p=0.048). In the active RA group, there was also a positive correlation between TNF-R and CRP (r:0.621; p=0,003). Both healthy and active RA group had significant positive correlation between ESR and CRP (r: 0.481; p=0.032 and r: 0,697; p=0,001 respectively). Conclusion: TNF-R can be the main pathophysiological factor and a marker showing activation. TNF-R can be very important in revealing the effect of TNF on the disease and the value of this effect in the treatment and ensuring the follow-up of the disease with CRP instead of ESR in activation.en_US
dc.identifier.citationKaya, F.Ö., Ceylan, Y., Öngen İpek, B. vd. (2021). Can Cytokines be used as an Activation Marker in Rheumatoid Arthritis?. Endocrine, Metabolic & Immune Disorders - Drug Targets, Bentham Science. 21(8), s. 1459-1465.en_US
dc.identifier.doi10.2174/1871530320666201019115030
dc.identifier.endpage1465en_US
dc.identifier.issn2212-3873
dc.identifier.issue8en_US
dc.identifier.pmid33076814en_US
dc.identifier.scopus2-s2.0-85116853589en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1459en_US
dc.identifier.urihttps://www.eurekaselect.com/article/110736
dc.identifier.urihttps://doi.prg/10.2174/1871530320666201019115030
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3671
dc.identifier.volume21en_US
dc.identifier.wosWOS:000689469900011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKaya, Fatih Öner
dc.institutionauthorCeylan, Yeşim
dc.institutionauthorÖngen İpek, Belkız
dc.institutionauthorÖzünal, Zeynep Güneş
dc.institutionauthorSezgin, Gülbüz
dc.institutionauthorNalbant, Selim
dc.language.isoenen_US
dc.publisherBentham Scienceen_US
dc.relation.ispartofEndocrine, Metabolic & Immune Disorders - Drug Targetsen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY00800
dc.subjectCRPen_US
dc.subjecterythrocyte sedimentation rateen_US
dc.subjectTNF- ?en_US
dc.subjectsoluble TNF- ? receptoren_US
dc.subjectIL-1Ben_US
dc.subjectIL-10en_US
dc.subjectDAS-28en_US
dc.titleCan Cytokines be used as an Activation Marker in Rheumatoid Arthritis?en_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu